>Exenatide LAR – so, nasal spray would be even better than a needle?<
Maybe so. I’m surprised NSTK longs don’t think this is a bigger (ouch!) deal.
The way AMLN and LLY are moving with little expedition on the LAR program reminds me of the way DNDN is moving without expedition on the BLA for Provenge.
Companies simply don’t act this way when they think they have a blockbuster in waiting!
If AMLN and LLY think LAR is not a blockbuster in waiting, why should anyone else think it is?
Market Data 
Markets 
AI
